It is becoming clear that a potential therapy targeting the Fas–FasL pathway in disease should consider the direct targeting of the pathogenic cells for specific diseases, such as tumor cells for cancer and immune cells for autoimmunity. This evidence concerns the gene FAS and Autoimmunity.